Characteristics and spatially-defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer

CONCLUSIONS: In this early-stage TNBC cohort, nearly 50% were PD-L1+ (SP142 companion assay) while 16% were PD-L1+ with the 22C3 companion assay. PD-L1+ TNBC had specific myeloid-derived and lymphoid features. Spatially-defined PD-L1+TIME were enriched in several clinically-actionable immune proteins. These data may inform future studies on combinatorial immunotherapies for patients with PD-L1+ TNBC.PMID:34108182 | DOI:10.1158/1078-0432.CCR-21-0343

Source: Clinical Genitourinary Cancer - June 10, 2021 Category: Cancer & Oncology Authors: Jodi M Carter Mei-Yin C Polley Roberto A Leon-Ferre Jason Sinnwell Kevin J Thompson Xue Wang Yaohua Ma David Zahrieh Jennifer M Kachergus Malvika Solanki Judy C Boughey Minetta C Liu James N Ingle Krishna R Kalari Fergus J Couch E Aubrey Thompson Matthew Source Type: research